Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Free Cash Flow (2016 - 2025)

Syndax Pharmaceuticals has reported Free Cash Flow over the past 11 years, most recently at -$69.5 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$69.5 million for Q4 2025, down 21.18% from a year ago — trailing twelve months through Dec 2025 was -$323.0 million (down 17.51% YoY), and the annual figure for FY2025 was -$323.2 million, down 17.56%.
  • Free Cash Flow for Q4 2025 was -$69.5 million at Syndax Pharmaceuticals, up from -$70.5 million in the prior quarter.
  • Over the last five years, Free Cash Flow for SNDX hit a ceiling of $100.7 million in Q4 2021 and a floor of -$95.2 million in Q1 2025.
  • Median Free Cash Flow over the past 5 years was -$41.6 million (2022), compared with a mean of -$43.2 million.
  • Biggest five-year swings in Free Cash Flow: surged 744.29% in 2021 and later tumbled 122.73% in 2022.
  • Syndax Pharmaceuticals' Free Cash Flow stood at $100.7 million in 2021, then tumbled by 122.73% to -$22.9 million in 2022, then plummeted by 80.61% to -$41.3 million in 2023, then crashed by 38.79% to -$57.4 million in 2024, then decreased by 21.18% to -$69.5 million in 2025.
  • The last three reported values for Free Cash Flow were -$69.5 million (Q4 2025), -$70.5 million (Q3 2025), and -$87.8 million (Q2 2025) per Business Quant data.